AIAISci
中文

Science community intelligence

Biotech science

Biotech league updates across protein design, genomics, cell systems, diagnostics, clinical signals, and biomanufacturing.

Reviewed signals
601
Evidence sources
721
Tracked fields
6
Biotech leagueProtein and Drug Design93 matching updates
clinical updateBiotecheditor reviewed
Rising signal62

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

Clinical/translation signal: Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Protein and Drug Design
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal62

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Clinical/translation signal: Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Protein and Drug Design
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal62

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Clinical/translation signal: Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Protein and Drug Design
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal62

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Clinical/translation signal: Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Protein and Drug Design
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal60

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Clinical/translation signal: Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Protein and Drug Design
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal60

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Clinical/translation signal: Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Protein and Drug Design
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal59

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Clinical/translation signal: pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Protein and Drug Design
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context